Effects of curcumin in pediatric epithelial liver tumors: Inhibition of tumor growth and alpha-fetoprotein in vitro and in vivo involving the NFkappaB- and the beta-catenin pathways

Oncotarget

Volumn 6, Issue 38, 2015, Pages 40680-40691

  Bortel, Nicola ^a   Armeanu Ebinger, Sorin ^a   Schmid, Evi ^a   Kirchner, Bettina ^a   Frank, Jan ^b   Kocher, Alexa ^b   Schiborr, Christina ^b   Warmann, Steven ^a   Fuchs, Jörg ^a   Ellerkamp, Verena ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF HOHENHEIM   (Germany)

Author keywords

Cisplatin; Curcumin; Hepatocellular carcinoma; Orthotopic tumor model; Pediatric

Indexed keywords

ALPHA FETOPROTEIN; BETA CATENIN; CISPLATIN; CURCUMIN; CYCLIN D; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ANTINEOPLASTIC AGENT; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG TISSUE LEVEL; FEMALE; HEPATOCELLULAR CARCINOMA CELL LINE; IC50; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MAXIMUM PLASMA CONCENTRATION; MICELLE; MONOTHERAPY; MOUSE; NONHUMAN; TUMOR XENOGRAFT; ANIMAL; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CHILD; DRUG EFFECTS; DRUG SCREENING; ENZYME IMMUNOASSAY; GENETICS; HUMAN; LIVER NEOPLASMS; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; NONOBESE DIABETIC MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; TUMOR CELL CULTURE; WESTERN BLOTTING;

ALPHA-FETOPROTEINS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BETA CATENIN; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CHILD; CURCUMIN; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IN VITRO TECHNIQUES; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84951025977     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5673     Document Type: Article

References (56)

1. Finegold MJ, Egler RA, Goss JA, Guillerman RP, Karpen SJ, Krishnamurthy R, O'Mahony CA. Liver tumors: pediatric population. Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2008; 14:1545-1556.
2. Aronson DC, Czauderna P, Maibach R, Perilongo G, Morl B. The treatment of hepatoblastoma: Its evolution and the current status as per the SIOPEL trials. Journal of Indian Association of Pediatric Surgeons. 2014; 19:201-207.
3. Lopez-Terrada D, Alaggio R, de Davila MT, Czauderna P, Hiyama E, Katzenstein H, Leuschner I, Malogolowkin M, Meyers R, Ranganathan S, Tanaka Y, Tomlinson G, Fabre M, Zimmermann A, Finegold MJ Children's Oncology Group Liver Tumor C. Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2014; 27:472-491.
4. Kelly D, Sharif K, Brown RM, Morl B. Hepatocellular carcinoma in children. Clinics in liver disease. 2015; 19:433-447.
5. Czauderna P. Adult type vs. Childhood hepatocellular carcinoma- are they the same or different lesions? Biology, natural history, prognosis, and treatment. Medical and pediatric oncology. 2002; 39:519-523.
6. Gupta SC, Kismali G, Aggarwal BB. Curcumin, a component of turmeric: From farm to pharmacy. BioFactors. 2013; 39:2-13.
7. Pramanik D, Campbell NR, Das S, Gupta S, Chenna V, Bisht S, Sysa-Shah P, Bedja D, Karikari C, Steenbergen C, Gabrielson KL, Maitra A. A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy. Oncotarget. 2012; 3:640-650.
8. Liang Y, Zheng T, Song R, Wang J, Yin D, Wang L, Liu H, Tian L, Fang X, Meng X, Jiang H, Liu J, Liu L. Hypoxiamediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1alpha inhibition in hepatocellular carcinoma. Hepatology. 2013; 57:1847-1857.
9. Ghosh D, Choudhury ST, Ghosh S, Mandal AK, Sarkar S, Ghosh A, Saha KD, Das N. Nanocapsulated curcumin: oral chemopreventive formulation against diethylnitrosamine induced hepatocellular carcinoma in rat. Chem Biol Interact. 2012; 195:206-214.
10. Wang WZ, Li L, Liu MY, Jin XB, Mao JW, Pu QH, Meng MJ, Chen XG, Zhu JY. Curcumin induces FasLrelated apoptosis through p38 activation in human hepatocellular carcinoma Huh7 cells. Life sciences. 2013; 92:352-358.
11. Schiborr C, Kocher A, Behnam D, Jandasek J, Toelstede S, Frank J. The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes. Molecular nutrition & food research. 2014; 58:516-527.
12. Suskind DL, Wahbeh G, Burpee T, Cohen M, Christie D, Weber W. Tolerability of Curcumin in Pediatric Inflammatory Bowel Disease: A Forced Dose Titration Study. J Pediatr Gastroenterol Nutr. 2013; 56:277-279.
13. Armeanu-Ebinger S, Wenz J, Seitz G, Leuschner I, Handgretinger R, Mau-Holzmann UA, Bonin M, Sipos B, Fuchs J, Warmann SW. Characterisation of the cell line HC-AFW1 derived from a pediatric hepatocellular carcinoma. PloS one. 2012; 7:e38223.
14. Aden DP, Fogel A, Plotkin S, Damjanov I, Knowles BB. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature. 1979; 282:615-616.
15. Ellerkamp V, Lieber J, Nagel C, Wenz J, Warmann SW, Fuchs J, Armeanu-Ebinger S. Pharmacological inhibition of beta-catenin in hepatoblastoma cells. Pediatric surgery international. 2013; 29:141-149.
16. Xu MX, Zhao L, Deng C, Yang L, Wang Y, Guo T, Li L, Lin J, Zhang L. Curcumin suppresses proliferation and induces apoptosis of human hepatocellular carcinoma cells via the wnt signaling pathway. International journal of oncology. 2013; 43:1951-1959.
17. Darbari A, Sabin KM, Shapiro CN, Schwarz KB. Epidemiology of primary hepatic malignancies in U.S. children. Hepatology. 2003; 38:560-566.
18. Kim H, Lee MJ, Kim MR, Chung IP, Kim YM, Lee JY, Jang JJ. Expression of cyclin D1, cyclin E, cdk4 and loss of heterozygosity of 8p, 13q, 17p in hepatocellular carcinoma: comparison study of childhood and adult hepatocellular carcinoma. Liver. 2000; 20:173-178.
19. Zhao D, Long XD, Lu TF, Wang T, Zhang WW, Liu YX, Cui XL, Dai HJ, Xue F, Xia Q. Metformin decreases IL-22 secretion to suppress tumor growth in an orthotopic mouse model of hepatocellular carcinoma. International journal of cancer Journal international du cancer. 2015; 136:2556-2565.
20. Portmann S, Fahrner R, Lechleiter A, Keogh A, Overney S, Laemmle A, Mikami K, Montani M, Tschan MP, Candinas D, Stroka D. Antitumor effect of SIRT1 inhibition in human HCC tumor models in vitro and in vivo. Mol Cancer Ther. 2013; 12:499-508.
21. Bagi CM, Gebhard DF, Andresen CJ. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma. European journal of gastroenterology & hepatology. 2012; 24:563-574.
22. Zhao GJ, Xu LX, Chu ES, Zhang N, Shen JY, Damirin A, Li XX. Establishment of an orthotopic transplantation tumor model of hepatocellular carcinoma in mice. World J Gastroenterol. 2012; 18:7087-7092.
23. Lee TK, Na KS, Kim J, Jeong HJ. Establishment of animal models with orthotopic hepatocellular carcinoma. Nuclear medicine and molecular imaging. 2014; 48:173-179.
24. Kim HJ, Park SY, Park OJ, Kim YM. Curcumin suppresses migration and proliferation of Hep3B hepatocarcinoma cells through inhibition of the Wnt signaling pathway. Molecular medicine reports. 2013; 8:282-286.
25. Metzler M, Pfeiffer E, Schulz SI, Dempe JS. Curcumin uptake and metabolism. BioFactors. 2013; 39:14-20.
26. Schiborr C, Eckert GP, Rimbach G, Frank J. A validated method for the quantification of curcumin in plasma and brain tissue by fast narrow-bore high-performance liquid chromatography with fluorescence detection. Anal Bioanal Chem. 2010; 397:1917-1925.
27. Schrader C, Schiborr C, Frank J, Rimbach G. Curcumin induces paraoxonase 1 in cultured hepatocytes in vitro but not in mouse liver in vivo. Br J Nutr. 2011; 105:167-170.
28. Wang K, Zhang T, Liu L, Wang X, Wu P, Chen Z, Ni C, Zhang J, Hu F, Huang J. Novel micelle formulation of curcumin for enhancing antitumor activity and inhibiting colorectal cancer stem cells. Int J Nanomedicine. 2012; 7:4487-4497.
29. Lao CD, Ruffin MTt, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, Crowell J, Rock CL, Brenner DE. Dose escalation of a curcuminoid formulation. BMC complementary and alternative medicine. 2006; 6:10.
30. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer research. 2001; 21:2895-2900.
31. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, Steward WP. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clinical cancer research: an official journal of the American Association for Cancer Research. 2004; 10:6847-6854.
32. Carroll RE, Benya RV, Turgeon DK, Vareed S, Neuman M, Rodriguez L, Kakarala M, Carpenter PM, McLaren C, Meyskens FL Jr, Brenner DE. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila). 2011; 4:354-364.
33. Ringman JM, Frautschy SA, Teng E, Begum AN, Bardens J, Beigi M, Gylys KH, Badmaev V, Heath DD, Apostolova LG, Porter V, Vanek Z, Marshall GA, Hellemann G, Sugar C, Masterman DL, et al. Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers Res Ther. 2012; 4:43.
34. Antony B, Merina B, Iyer VS, Judy N, Lennertz K, Joyal S. A Pilot Cross-Over Study to Evaluate Human Oral Bioavailability of BCM-95CG (Biocurcumax), A Novel Bioenhanced Preparation of Curcumin. Indian journal of pharmaceutical sciences. 2008; 70:445-449.
35. Cuomo J, Appendino G, Dern AS, Schneider E, McKinnon TP, Brown MJ, Togni S, Dixon BM. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. Journal of natural products. 2011; 74:664-669.
36. Gota VS, Maru GB, Soni TG, Gandhi TR, Kochar N, Agarwal MG. Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. Journal of agricultural and food chemistry. 2010; 58:2095-2099.
37. Kanai M, Imaizumi A, Otsuka Y, Sasaki H, Hashiguchi M, Tsujiko K, Matsumoto S, Ishiguro H, Chiba T. Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers. Cancer chemotherapy and pharmacology. 2012; 69:65-70.
38. Sasaki H, Sunagawa Y, Takahashi K, Imaizumi A, Fukuda H, Hashimoto T, Wada H, Katanasaka Y, Kakeya H, Fujita M, Hasegawa K, Morimoto T. Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull. 2011; 34:660-665.
39. Vareed SK, Kakarala M, Ruffin MT, Crowell JA, Normolle DP, Djuric Z, Brenner DE. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2008; 17:1411-1417.
40. Mu H, Holm R, Mullertz A. Lipid-based formulations for oral administration of poorly water-soluble drugs. International journal of pharmaceutics. 2013; 453:215-224.
41. Sung B, Kunnumakkara AB, Sethi G, Anand P, Guha S, Aggarwal BB. Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol Cancer Ther. 2009; 8:959-970.
42. Lin LI, Ke YF, Ko YC, Lin JK. Curcumin inhibits SK-Hep-1 hepatocellular carcinoma cell invasion in vitro and suppresses matrix metalloproteinase-9 secretion. Oncology. 1998; 55:349-353.
43. Liang HH, Wei PL, Hung CS, Wu CT, Wang W, Huang MT, Chang YJ. MicroRNA-200a/b influenced the therapeutic effects of curcumin in hepatocellular carcinoma (HCC) cells. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013; 34:3209-3218.
44. Zhang H, Yu T, Wen L, Wang H, Fei D, Jin C. Curcumin enhances the effectiveness of cisplatin by suppressing CD133 cancer stem cells in laryngeal carcinoma treatment. Experimental and therapeutic medicine. 2013; 6:1317-1321.
45. Trujillo J, Chirino YI, Molina-Jijon E, Anderica-Romero AC, Tapia E, Pedraza-Chaverri J. Renoprotective effect of the antioxidant curcumin: Recent findings. Redox biology. 2013; 1:448-456.
46. Chen J, Liu J, Jin R, Shen J, Liang Y, Ma R, Lin H, Liang X, Yu H, Cai X. Cytoplasmic and/or Nuclear Expression of beta-Catenin Correlate with Poor Prognosis and Unfavorable Clinicopathological Factors in Hepatocellular Carcinoma: A Meta-Analysis. PloS one. 2014; 9:e111885.
47. Chen Z, Zhu J, Huang C, Lian F, Wu G, Zhao Y. The association between three cyclooxygenase-2 polymorphisms and hepatocellular carcinoma risk: a meta-analysis. PloS one. 2015; 10:e0118251.
48. Ning L, Wentworth L, Chen H, Weber SM. Downregulation of Notch1 signaling inhibits tumor growth in human hepatocellular carcinoma. American journal of translational research. 2009; 1:358-366.
49. Yoysungnoen P, Wirachwong P, Changtam C, Suksamrarn A, Patumraj S. Anti-cancer and anti-angiogenic effects of curcumin and tetrahydrocurcumin on implanted hepatocellular carcinoma in nude mice. World J Gastroenterol. 2008; 14:2003-2009.
50. Liu H, Liang Y, Wang L, Tian L, Song R, Han T, Pan S, Liu L. In Vivo and In Vitro Suppression of Hepatocellular Carcinoma by EF24, a Curcumin Analog. PloS one. 2012; 7:e48075.
51. Debruyne EN, Delanghe JR. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. Clinica chimica acta; international journal of clinical chemistry. 2008; 395:19-26.
52. Kumar B, Yadav A, Hideg K, Kuppusamy P, Teknos TN, Kumar P. A novel curcumin analog (h-4073) enhances the therapeutic efficacy of Cisplatin treatment in head and neck cancer. PloS one. 2014; 9:e93208.
53. Lopez-Terrada D, Cheung SW, Finegold MJ, Knowles BB. Hep G2 is a hepatoblastoma-derived cell line. Human pathology. 2009; 40:1512-1515.
54. Lieber J, Kirchner B, Eicher C, Warmann SW, Seitz G, Fuchs J, Armeanu-Ebinger S. Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells. Pediatric blood & cancer. 2010; 55:1089-1095.
55. Berenbaum MC. Criteria for analyzing interactions between biologically active agents. Advances in cancer research. 1981; 35:269-335.
56. Ellerkamp V, Armeanu-Ebinger S, Wenz J, Warmann SW, Schafer J, Ruck P, Fuchs J. Successful establishment of an orthotopic hepatoblastoma in vivo model in NOD/LtSz-scid IL2Rgammanull mice. PloS one. 2011; 6:e23419.